Morgan Stanley Mei Pharma, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.21 - $0.35 $268,603 - $447,672	1,279,063 Added 691.64%	1,463,996 $336,000
Q4 2022 Feb 14, 2023	BUY	$0.22 - $0.41 $15,418 - $28,734	70,083 Added 61.02%	184,933 $44,000
Q3 2022 Nov 14, 2022	SELL	$0.41 - $0.64 $26,039 - $40,647	-63,511 Reduced 35.61%	114,850 $44,000
Q2 2022 Oct 27, 2022	SELL	$0.42 - $0.65 $151,081 - $233,816	-359,717 Reduced 66.85%	178,361 $108,000
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $151,081 - $233,816	-359,717 Reduced 66.85%	178,361 $108,000

Q1 2022 Oct 27, 2022	BUY	$0.54 - $2.74 $194,247 - $985,624	359,717 Added 201.68%	538,078 $324,000
Q1 2022 May 13, 2022	BUY	$0.54 - $2.74 $241,668 - $1.23 Million	447,535 Added 494.28%	538,078 $324,000
Q4 2021 Feb 14, 2022	BUY	$2.33 - $3.37 $107,063 - $154,851	45,950 Added 103.04%	90,543 $242,000
Q3 2021 Nov 15, 2021	BUY	$2.52 - $2.99 $112,374 - $133,333	44,593 New	44,593 $124,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $373M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.